Nephro Care opened higher at ₹86.00, compared with its previous close of ₹83.85. During today's session, the stock has traded between ₹85.00 and ₹87.60, with an average traded price of ₹86.36. It is currently showing an upward intraday trend.
return calculator
Time Period
An investment of ₹10,000 made 3 years ago in Nephro Care is now worth
₹ 4,818.00
resulting in a loss of
₹ 5,182.00 (51.82%)
invest now
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+2.65 (+3.16%)
Day High
₹87.60
Day Low
₹85.00
Day Open
₹86.00
Prev Close
₹83.85
Volume
9,600
Value Traded
₹0.08 Cr
1W Return
-0.46%
1M Return
-7.19%
3M Return
21.06%
6M Return
7.05%
1Y Return
-39.64%
Fundamentals
Market Cap (₹ Cr.)
143
PE Ratio
41.10
PB Ratio
2.43
Dividend Yield
-
ROE
5.92%
ROCE
8.35%
Book Value (₹)
34.49
Face Value (₹)
10.00
EPS (TTM)
0.98
Industry PE
-
Beta
-
Debt to Equity
-
Investment Returns
1 Week
-0.46%
6 Week
-
1 Month
-7.19%
3 Month
21.06%
9 Month
-22.56%
Financials
Yearly
Consolidated
All values in ₹ crores
0.90
Mar 26
Share Holding Pattern
Promoter61.71%
FII0.96%
DII1.29%
Retails & Others30.34%
Updates
23Jun
Nephro Care closes trading window from July 1 till Q1FY27 results
Nephro Care India Limited has closed its trading window for all Designated Persons from July 1, 2026, until 48 hours after the Q1FY27 results declaration. The Board meeting date to approve the unaudited financial results for the quarter ended June 30, 2026, will be announced later.
3mo ago
28May
Nephro Care India reports FY26 profit of ₹336.89 lakh
Nephro Care India Limited reported a net profit of ₹336.89 lakh for the financial year ended 31 March 2026, with revenue from operations rising to ₹8,873.48 lakh from ₹4,603.11 lakh in the previous year. The statutory auditor issued an unmodified opinion, though it drew attention to a GST write-off of ₹86.88 lakh and a pending reconciliation of ₹247.87 lakh in GST credits. The Board also approved the appointment of M/s M. Dutta & Associates as the internal auditor for FY27.
4mo ago
1Apr
Nomura Initiates Buy Rating on Nephrocare India with Target Price of Rs 605
Nomura has initiated coverage on Nephrocare India with a Buy rating and Rs 605 target price. The brokerage cites the company's sticky dialysis services with recurring revenue, strong positioning of NephroPlus in concentrated markets, and expects 18.3% EBITDA CAGR driven by mid-to-high-teen revenue growth and stable margins.
